Monoclonal antibodies in immunotherapy
Journal of Prescribing Practice · 2019
DOI: 10.12968/jprp.2019.1.1.26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Prescribing Practice, 2019. Verfasst von Roy Jefferis. Die Arbeit nennt 13 Literaturangaben.
Abstract (Originalsprache)
The bench-to-bedside ideal is being realised for both humoral and cellular immunotherapy. Monoclonal antibodies (mAbs) are established in the clinic, but continuous development has resulted in progression from mouse/human chimeric to humanised, ‘fully’ human, antibody–drug conjugates, biosimilars and biobetter therapeutics. The objective has been to minimise their potential for immunogenicity and to elucidate and exploit their multiple mechanisms of action (MoA). However, exploitation of these advances within the NHS is limited due their high cost. Consequently, the National Institute for Health and Care Excellence (NICE) offers evidence-based recommendations for the availability of approved mAbs, and other ‘speciality drugs’ within the NHS; alternative avenues for funding may be available while the efficacy of such drug is being fully evaluated. More cost-effective treatment is being achieved through patient stratification following genome sequencing and identification of polymorphisms that predispose people to disease susceptibilities and their responses to particular drugs or combinations of therapeutics.
Zitieren
APA
Jefferis, R. (2019). Monoclonal antibodies in immunotherapy. Journal of Prescribing Practice. https://doi.org/10.12968/jprp.2019.1.1.26
Vancouver
Jefferis R. Monoclonal antibodies in immunotherapy. Journal of Prescribing Practice. 2019. doi:10.12968/jprp.2019.1.1.26
BibTeX
@article{Jefferis2019,
author = {Jefferis, Roy},
title = {Monoclonal antibodies in immunotherapy},
journal = {Journal of Prescribing Practice},
year = {2019},
doi = {10.12968/jprp.2019.1.1.26}
}
EUVIMED